Feb 24, 2020 / 03:55PM GMT
Michael Leonidovich Ryskin - BofA Merrill Lynch, Research Division - Associate
Here with us, we have Brian McKeon from -- CFO of IDEXX; and Tina Hunt, Head of VetLab for IDEXX Labs. We'll follow the same format, about 30 minutes of fireside chat and then some Q&A. Last session before lunch. So just hold on.
So maybe just to start, recap of where you are at the end of 2019, beginning of 2020, sort of what's your view of the market? How it's evolved? And sort of what are the big takeaways you have from us -- from the last year?
Brian P. McKeon - IDEXX Laboratories, Inc. - CFO, Executive VP & Treasurer
Yes. We had a very good 2019 as a company, very much aligned with our long-term performance goals. A key metric that we focus on is our CAG Diagnostics recurring revenue growth. So think of that as the recurring annuity revenues of the business, high margin, recurring revenue is about 75% of our total revenues. And normalized, they grew roughly 12% last year, 11% in the U.S., 13% internationally. Those metrics are all very well aligned with our long
IDEXX Laboratories Inc at Bank of America Merrill Lynch Animal Health Summit Transcript
Feb 24, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers